Sign up
Pharma Capital

Arix Bioscience has 'keen eye' on Australia as it takes stake in ASX-listed Pharmaxis

Ed Rayner, investment director at Arix Bioscience Plc (LON:ARIX), discusses the decision to make their first investment in Australia by leading a sizeable funding round for ASX-listed Pharmaxis (ASX:PXS).

The life science investment group will take an 11% interest in Pharmaxis, which is developing treatments for inflammation and fibrosis.

It's their first 'VIPE'  or Venture Investment in Public Equity deal, where Arix plans to take a hands-on role in the development of the company as well as providing finance.

 

View full ARIX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.